Literature DB >> 23595282

Human mesenchymal stem cells in the treatment of neurological diseases.

Katarzyna Drela1, Patrycja Siedlecka, Anna Sarnowska, Krystyna Domanska-Janik.   

Abstract

Here we provide a comprehensive data on the unique features of mesenchymal stem cells (MSCs) which makes them feasible and preferred candidate for cell-based therapy in neurological clinic. From this point of view the most important features of these cells are: (1) availability from autologous sources independently from age of patient; (2) extensive expansion in vitro; (3) immunomodulatory "bystander" function after transplantation in vivo; (4) potentiality to protect, repair or eventually replace impaired or dysfunctional host cells. For complete this last task of functional regeneration of central nervous system, we have to take advantages of MSCs capability for transient, time-locked proliferation, migration to site of injury and their commitment to neuronal differentiation. However, if we are to make progress in the use of MSCs for therapy in the clinic it will be necessary to establish more unified, advanced standards for cells processing in vitro as well as safer and improved procedures for their delivery in vivo.

Entities:  

Mesh:

Year:  2013        PMID: 23595282

Source DB:  PubMed          Journal:  Acta Neurobiol Exp (Wars)        ISSN: 0065-1400            Impact factor:   1.579


  13 in total

1.  Mesenchymal stem cells inhibited the inflammation and oxidative stress in LPS-activated microglial cells through AMPK pathway.

Authors:  Dayong Cao; Haowen Qiao; Dejiao He; Xingping Qin; Qian Zhang; Yu Zhou
Journal:  J Neural Transm (Vienna)       Date:  2019-11-09       Impact factor: 3.575

Review 2.  A New Chapter for Mesenchymal Stem Cells: Decellularized Extracellular Matrices.

Authors:  Yagiz Anasiz; Riza Koksal Ozgul; Duygu Uckan-Cetinkaya
Journal:  Stem Cell Rev Rep       Date:  2017-10       Impact factor: 5.739

3.  The organotypic longitudinal spinal cord slice culture for stem cell study.

Authors:  Joanna Sypecka; Sylwia Koniusz; Maria Kawalec; Anna Sarnowska
Journal:  Stem Cells Int       Date:  2015-01-31       Impact factor: 5.443

4.  Neuroprotective and antiapoptotic activity of lineage-negative bone marrow cells after intravitreal injection in a mouse model of acute retinal injury.

Authors:  Anna Machalińska; Dorota Rogińska; Ewa Pius-Sadowska; Miłosz P Kawa; Edyta Paczkowska; Michał Rudnicki; Renata Lejkowska; Bartłomiej Baumert; Barbara Wiszniewska; Bogusław Machaliński
Journal:  Stem Cells Int       Date:  2015-02-24       Impact factor: 5.443

Review 5.  Concise Review: Mesenchymal Stem Cell Therapy for Pediatric Disease: Perspectives on Success and Potential Improvements.

Authors:  Christopher R Nitkin; Tracey L Bonfield
Journal:  Stem Cells Transl Med       Date:  2016-09-13       Impact factor: 6.940

6.  Cerebrospinal fluid from Alzheimer's disease patients as an optimal formulation for therapeutic application of mesenchymal stem cells in Alzheimer's disease.

Authors:  Jeongmin Lee; Soo Jin Kwon; Jang Hoon Kim; Hyemin Jang; Na Kyung Lee; Jung Won Hwang; Jong Hwa Kim; Jong Wook Chang; Duk L Na
Journal:  Sci Rep       Date:  2019-01-24       Impact factor: 4.379

7.  Early Intravenous Infusion of Mesenchymal Stromal Cells Exerts a Tissue Source Age-Dependent Beneficial Effect on Neurovascular Integrity and Neurobehavioral Recovery After Traumatic Cervical Spinal Cord Injury.

Authors:  Reaz Vawda; Anna Badner; James Hong; Mirriam Mikhail; Alam Lakhani; Rachel Dragas; Kristiana Xhima; Tanya Barretto; Clifford L Librach; Michael G Fehlings
Journal:  Stem Cells Transl Med       Date:  2019-03-26       Impact factor: 6.940

8.  Synergistic Improvement in Children with Cerebral Palsy Who Underwent Double-Course Human Wharton's Jelly Stem Cell Transplantation.

Authors:  Xiaojun Fu; Rongrong Hua; Xiaodong Wang; Peishen Wang; Long Yi; Aixue Yu; Jing Yang; Yan Li; Yihua An
Journal:  Stem Cells Int       Date:  2019-09-17       Impact factor: 5.443

9.  In vivo immune interactions of multipotent stromal cells underlie their long-lasting pain-relieving effect.

Authors:  Wei Guo; Satoshi Imai; Jia-Le Yang; Shiping Zou; Mineo Watanabe; Yu-Xia Chu; Zaid Mohammad; Huakun Xu; Kamal D Moudgil; Feng Wei; Ronald Dubner; Ke Ren
Journal:  Sci Rep       Date:  2017-08-31       Impact factor: 4.379

10.  Human Recombinant Peptide Sponge Enables Novel, Less Invasive Cell Therapy for Ischemic Stroke.

Authors:  Michiyuki Miyamoto; Kentaro Nakamura; Hideo Shichinohe; Tomohiro Yamauchi; Masaki Ito; Hisayasu Saito; Masahito Kawabori; Toshiya Osanai; Tasuku Sasaki; Kiyohiro Houkin; Satoshi Kuroda
Journal:  Stem Cells Int       Date:  2018-04-08       Impact factor: 5.443

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.